Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 2/20 | 0.65 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.65 |
| ▸ | RELA | Q04206 | 2/20 | 0.65 |
| ▸ | FPR2 | P25090 | 12/20 | 0.59 |
| ▸ | PPARG | P37231 | 3/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL590254 | 1.00 | NFKB1 (0.65) | NFKB1NFKB2RELAFPR2PPARG | |
| SCHEMBL29564346 | 1.00 | NFKB1 (0.65) | NFKB1NFKB2RELAFPR2PPARG | |
| SCHEMBL29935444 | 1.00 | NFKB1 (0.65) | NFKB1NFKB2RELAFPR2PPARG | |
| SCHEMBL22956003 | 1.00 | NFKB1 (0.65) | NFKB1NFKB2RELAFPR2PPARG | |
| SCHEMBL590256 | 1.00 | NFKB1 (0.65) | NFKB1NFKB2RELAFPR2PPARG | |
| SCHEMBL590255 | 1.00 | NFKB1 (0.65) | NFKB1NFKB2RELAFPR2PPARG | |
| SCHEMBL588778 | 0.94 | NFKB1 (0.61) | NFKB1NFKB2RELAFPR2PPARG | |
| SCHEMBL588777 | 0.94 | NFKB1 (0.61) | NFKB1NFKB2RELAFPR2PPARG | |
| SCHEMBL588776 | 0.94 | NFKB1 (0.61) | NFKB1NFKB2RELAFPR2PPARG | |
| SCHEMBL588779 | 0.94 | NFKB1 (0.61) | NFKB1NFKB2RELAFPR2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240165069-A1 | METHODS FOR TREATING DYSGEUSIA AND OTHER LINGERING SYMPTOMS ASSOCIATED WITH SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 INFECTIONADN CORONAVIRUS DISEASE 2019 | NOCENDRA, INC | 2024-05-23 | — | — | US | claimed |
| WO-2022178249-A1 | METHOD FOR TREATING DYSGEUSIA AND OTHER SYMPTOMS ASSOCIATED WITH COVID-19 | NOCENDRDA, INC. (US) | 2022-08-25 | — | — | WO | claimed |
| US-20240165069-A1 | METHODS FOR TREATING DYSGEUSIA AND OTHER LINGERING SYMPTOMS ASSOCIATED WITH SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 INFECTIONADN CORONAVIRUS DISEASE 2019 | NOCENDRA, INC | 2024-05-23 | — | — | US | disclosed |
| US-20230355562-A1 | METHODS FOR STABILIZING ATHEROSCLEROTIC PLAQUES USING LIPOXINS, RESOLVINS, AND ANALOGS THEREOF | ADA FORSYTH INSTITUTE, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230355562-A1 | METHODS FOR STABILIZING ATHEROSCLEROTIC PLAQUES USING LIPOXINS, RESOLVINS, AND ANALOGS THEREOF | ADA FORSYTH INSTITUTE, INC. | 2023-11-09 | — | — | US | disclosed |
| WO-2022178249-A1 | METHOD FOR TREATING DYSGEUSIA AND OTHER SYMPTOMS ASSOCIATED WITH COVID-19 | NOCENDRDA, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
| WO-2021021552-A1 | SYNTHESIS OF PRO-RESOLVING ANALOGS AND COMPOSITIONS THEREFOR | NOCENDRA INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| US-20200330551-A1 | COMPOSITIONS AND METHODS OF TREATING CANCER USING LIPID AGONISTS AND RECEPTORS THEREOF | ADA FORSYTH INSTITUTE, INC. | 2020-10-22 | — | — | US | disclosed |
| US-20200138763-A1 | METHODS FOR INCREASING ORAL OSTEOGENESIS USING LIPOXIN A4 (LXA4) AND ITS ANALOGS | ADA FORSYTH INSTITUTE, INC. | 2020-05-07 | — | — | US | disclosed |
| US-10434080-B2 | Methods for increasing oral osteogenesis using lipoxin A4 (LXA4) and its analogs | FORSYTH DENTAL INFIRMARY FOR CHILDREN (US) | 2019-10-08 | — | — | US | disclosed |
| US-10322102-B2 | Benzo lipoxin analogues | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2019-06-18 | — | — | US | disclosed |
| US-20100152290-A1 | Benzo Lipoxin Analogues | UNIVERSITY OF SOUTHERN CALIFORNIA | 2010-06-17 | — | — | US | disclosed |
| US-20100152290-A1 | Benzo Lipoxin Analogues | UNIVERSITY OF SOUTHERN CALIFORNIA | 2010-06-17 | — | — | US | disclosed |
| US-7683193-B2 | Inflammation, autoimmune disease and abnormal cell proliferation; analogs of 15-epi-lipoxin A4; e.g. (5S,6R,E)-methyl 5,6-dihydroxy-8-(2-(1-hydroxyhexyl)phenyl)oct-7-enoate | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683193-B2 | Inflammation, autoimmune disease and abnormal cell proliferation; analogs of 15-epi-lipoxin A4; e.g. (5S,6R,E)-methyl 5,6-dihydroxy-8-(2-(1-hydroxyhexyl)phenyl)oct-7-enoate | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683193-B2 | Inflammation, autoimmune disease and abnormal cell proliferation; analogs of 15-epi-lipoxin A4; e.g. (5S,6R,E)-methyl 5,6-dihydroxy-8-(2-(1-hydroxyhexyl)phenyl)oct-7-enoate | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2010-03-23 | — | — | US | disclosed |
| US-20090311201-A1 | LIPOXIN ANALOGS AND METHODS FOR THE TREATMENT OF PERIODONTAL DISEASE | TRUSTEES OF BOSTON UNIVERSITY (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090311201-A1 | LIPOXIN ANALOGS AND METHODS FOR THE TREATMENT OF PERIODONTAL DISEASE | TRUSTEES OF BOSTON UNIVERSITY (US) | 2009-12-17 | — | — | US | disclosed |
| US-20060270734-A1 | Benzo lipoxin analogues | UNIVERSITY OF SOUTHERN CALIFORNIA | 2006-11-30 | — | — | US | disclosed |
| US-20050203184-A1 | Benzo lipoxin analogues | PETASIS NICOS A (US) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203184-A1 | Benzo lipoxin analogues | ALOX15B, ALOX12, ALOX15 | NFKB1 175/4885NFKB2 265/4885RELA 546/4885 |
| US-10434080-B2 | Methods for increasing oral osteogenesis using lipoxin A4 (LXA4) and its analogs | LOXL4, LTA4H, BMP4 | NFKB1 1316/4885NFKB2 1596/4885RELA 2209/4885 |
| US-20090311201-A1 | LIPOXIN ANALOGS AND METHODS FOR THE TREATMENT OF PERIODONTAL DISEASE | ALOX5, ALOX15B, ALOX12 | NFKB1 343/4885NFKB2 450/4885RELA 496/4885 |
| US-20200138763-A1 | METHODS FOR INCREASING ORAL OSTEOGENESIS USING LIPOXIN A4 (LXA4) AND ITS ANALOGS | LOXL4, LTA4H, BMP4 | NFKB1 1316/4885NFKB2 1596/4885RELA 2209/4885 |
| US-20230355562-A1 | METHODS FOR STABILIZING ATHEROSCLEROTIC PLAQUES USING LIPOXINS, RESOLVINS, AND ANALOGS THEREOF | ALOX15B, ALOX15, ALOX5 | NFKB1 1222/4885NFKB2 2037/4885RELA 2412/4885 |
| US-20100152290-A1 | Benzo Lipoxin Analogues | ALOX15B, ALOX12, ALOX15 | NFKB1 175/4885NFKB2 265/4885RELA 546/4885 |
| US-10322102-B2 | Benzo lipoxin analogues | ALOX15B, ALOX12, ALOX15 | NFKB1 175/4885NFKB2 265/4885RELA 546/4885 |
| US-20200330551-A1 | COMPOSITIONS AND METHODS OF TREATING CANCER USING LIPID AGONISTS AND RECEPTORS THEREOF | PLA2R1, LPAR1, LPAR5 | NFKB1 1863/4885NFKB2 2026/4885RELA 1038/4885 |
| US-20060270734-A1 | Benzo lipoxin analogues | ALOX15B, ALOX12, ALOX15 | NFKB1 175/4885NFKB2 265/4885RELA 546/4885 |
| US-20240165069-A1 | METHODS FOR TREATING DYSGEUSIA AND OTHER LINGERING SYMPTOMS ASSOCIATED WITH SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 INFECTIONADN CORONAVIRUS DISEASE 2019 | LTA4H, LTB4R2, LTB4R | NFKB1 3461/4885NFKB2 3421/4885RELA 3077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.